

Your reliable API partner from India



YOUR RELIABLE PARTNER FROM INDIA

Smilax, the inspiration for our name, is a genus of 300-350 berries and plants that provide sustenance, shelter, and are of great medicinal value to the entire world.

At Smilax Laboratories Limited, we aspire to be the reliable source for API needs of pharmaceutical companies worldwide. Organically tuned to evolve, adapt and flourish, brand Smilax is making its presence felt in US, Europe, Japan within just five years of its inception.

VISION

Smilax shall be leading research & manufacturing partner in Active Pharmaceutical Ingredients & Advanced Drug intermediates pursuing chemistry for sustainable growth.

MISSION

We shall ensure quality, reliability and continuous innovation thereby enhancing the sustainability & value for all stakeholders.

STRATEGY

Our goal is to be a preferred provider of Active Pharmaceutical Ingredients and Advanced Drug intermediates for the Global Pharmaceutical Companies.

We use our core competence in developing cost effective chemistry solutions with regulatory compliance.

We leverage on the group's financial strength, global presence in infrastructure and environment engineering capabilities.

We invest in scale, capacity, quality and chemistry solutions to enable efficient outsourcing for our Global Pharmaceutical Customers.

Smilax is promoted by USD 1.5 billion Hyderabad based Ramky Group, a leader in Infrastructure and Environment Engineering.

All key functions are headed by best-in-class pharma professionals.

Received 'Outstanding Exports Award' in Bulk Drugs Category for 3 Consecutive years from Government of India.

Smilax manufactures APIs, Advanced Drug Intermediates and Pellets for global pharma companies

Built up Area of 350,000 sft

475 Kl multiple block facility

Plan to scale up to 1200 kl

WHY SMILAX

REGULATORY APPROVALS



- Facilities audited and approved by USFDA and European regulatory agency.
- Smilax is an approved source for many prestigious clients, including the top five in EU, Japan, Korea and India.
- Received approval for Omeprazole CEP from EDQM
- Both sites are approved by WHO

RESEARCH & DEVELOPMENT



- State of the art R&D centre manned by a 40 member team
- Equipped with a Kilo Lab facility, Advanced analytical infrastructure

QUALITY



- Facilities to meet cGMP requirements
- EHS 100% with an advantage of group expertise.

PRODUCT PORTFOLIO

APIs Offered

Product	Therapeutic Category	Product	Therapeutic Category
Amlodipine Besylate	Anti-Hypertensive / Anti-Anginal	Metformin	Anti-Diabetic
Atomoxetine	Anti-Depressant / Anti-Psychotic	Methocarbamol	Muscle Relaxant
Azilsartan	Anti-Hypertensive / Anti-Anginal	Olanzapine	Anti-Depressant / Anti-Psychotic
Blonanserin	Anti-Depressant / Anti-Psychotic	Omeprazole	Anti-Ulcerative
Candesartan Cilexetil	Anti-Hypertensive / Anti-Anginal	Omeprazole CEP	Anti-Ulcerative
Citalopram HBr	Anti-Depressant / Anti-Psychotic	Omeprazole Sodium	Anti-Ulcerative
Cloperastine	Anti-Histamine	Pantoprazole Sodium Sesquihydrate	Anti-Ulcerative
Escitalopram Oxalate	Anti-Depressant / Anti-Psychotic	Pioglitazone	Anti-Diabetic
Esomeprazole Mg Trihydrate	Anti-Ulcerative	Repaglinide	Anti-Diabetic
Esomeprazole Sodium	Anti-Ulcerative	Risperidone	Anti-Depressant / Anti-Psychotic
Guaifenesin	Muscle Relaxant	Sildenafil Citrate	Erectile Dysfunction
Hydrochlorothiazide	Anti-Hypertensive / Anti-Anginal	Sumatriptan Succinate	Anti-Migraine
Irbesartan	Anti-Hypertensive / Anti-Anginal	Telmisartan	Anti-Hypertensive / Anti-Anginal
Losartan Potassium	Anti-Hypertensive / Anti-Anginal	Valsartan	Anti-Hypertensive / Anti-Anginal

APIs Under Scale up / Development

Product	Therapeutic Category	Product	Therapeutic Category
AzilsartanMedoxomil	Anti-Hypertensive / Anti-Anginal	Linezolid	Anti-Biotic
Apixaban	Anti-Coagulant	MemantineHcl	Anti-Depressant/Anti-Psychot
ClopidogrelBisulfate Form II	Anti-Platelet	Mirabegron	Anti-Spasmodic
Clozapine	Anti-Depressant / Anti-Psychotic	OlmesartanMedoxomil	Anti-Hypertensive/Anti-Angin
Dabigatran	Anti-Coagulant	Prasugrel	Anti-Platelet
Dapagliflozin	Anti-Diabetic	Ranolazine	Anti-Hypertensive/Anti-Angir
Duloxetine	Anti-Depressant / Anti-Psychotic	Rivaroxaban	Anti-Coagulant
Empagliflozin	Anti-Diabetic	Saxagliptin	Anti-Diabetic
Fluoxetine	Anti-Depressant / Anti-Psychotic	Sitagliptin Phosphate	Anti-Diabetic
Ipragliflozin	Anti-Diabetic	Tadalafil	Erectile Dysfunction
Levocetirizine Di Hcl	Anti-Histamine	Tapentadol	Anti-Analgesics
Linagliptin	Anti-Diabetic	Vildagliptin	Anti-Diabetic

Pellets Offered

Product	Therapeutic Category	
Esomeprazole Pellets 8.5%, 22.5%	Anti-Ulcerative	
Itraconazole Pellets 22%, 40% 44%	Anti-Fungal	
Lansoprazole Pellets 8.5%	Anti-Ulcerative	
Omeprazole Pellets 7.5% 8.5% 10%	Anti-Ulcerative	
Pantoprazole Sodium Pellets 15%, 25%	Anti-Ulcerative	

Pellets Under Development

Product	Therapeutic Category	
Domperidone Immediate Release Pellets 10%, 20%, 30%	Anti-Ulcerative	
Domperidone Sustained Release Pellets 22%, 30%	Anti-Ulcerative	
Duloxetine HCl Pellets 16%, 17%, 19%, 20%	Anti-Depressant / Anti-Psychotic	
Esomeprazole Pellets 15%, 24%	Anti-Ulcerative	
Itraconazole Pellets 20%, 60%	Anti-Fungal	
Omeprazole Pellets 10%, 15%, 20%, 22.5%	Anti-Ulcerative	
Orlistat Immediate Release Pellets 40%, 50%	Anti-Obesity	
Pantoprazole Sodium Pellets 22.5%, 30%	Anti-Ulcerative	
Rabeprazole Sodium Pellets 12%, 15%, 22.5%	Anti-Ulcerative	
TamsulosinHCl Sustained Release Pellets 0.2%, 0.4%, 0.12%, 0.16%	ВРН	
Blend Pellets of Omeprazole Pellets 20mg (7.5%) &	Anti-Ulcerative	
Domperidone Pellets IR 10mg (10%)	Anti-Ulcerative	

DC Granules Under Development

Product	Therapeutic Category	
Guaifenesin DC Granules 95.0% W/W	Muscle Relexant	
Metformin Hydrochloride DC Granules 94.16%	Anti-Daibetic	
Metformin Hydrochloride DC Granules 95.24%	Anti-Daibetic	1
Paracetamol / Acetaminophen DC Granules 79.37%	Anti-Analgesics	911
Paracetamol / Acetaminophen DC Granules 90.0%	Anti-Analgesics	
Paracetamol / Acetaminophen DC Granules 83.30%	Anti-Analgesics	

Scale, Quality and Compliance for a Reliable Partnership



Smilax Laboratories Limited, Unit-I, Plot No: 12/A, Phase - III, IDA, Jeedimetla, Hyderabad-500 055, Telangana, India. T: +91 40 2309 0260, +91 40 2319 1777 F: +91 40 2309 5239

E: info@smilaxlabs.com www.smilaxlabs.com

Disclaimer: "Smilax Laboratories Limited respects Patent laws and conventions of Pharmaceuticals as applicable in different countries. Products covered by valid patents are not offered or supplied for commercial use in those countries. It is Buyer's / Customer's responsibility to ensure that such commercial activity does not infringe any applicable patent rights".